TriSalus Life Sciences Inc. (TLSI) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, TriSalus Life Sciences Inc. (NASDAQ: TLSI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $3.86 (-1.78% 1D, market cap $237.7M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 4/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, TLSI ranks #808 in composite RQD confidence.
Within the Health Care sector (Medical Specialities), TLSI carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 84.6%, and ROIC of -35.0%. By comparison, BDSX (Biodesix Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $260.8M) and XGN (Exagen Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $210.8M). Among the 5-stock peer group, TLSI leads on earnings multiple (N/A) while YDES leads on capital efficiency (-20.0% ROIC).
Per TLSI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001826667), TriSalus Life Sciences Inc. generated $45.2M in revenue (+53.4% YoY), -$39.2M in net income, and -$18.9M in free cash flow against $35.3M in total assets and $33.0M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 84.6% Gross Margin
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While TLSI currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.40) and Max Pain ($4.05) forces dealer call-delta covering toward $8.35.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
TriSalus Life Sciences Inc. (TLSI) slipped -1.78% to $3.86, trading at 29% of its 52-week range ($2.2 – $7.95). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
WESTMINSTER, Colo., October 29, 2026--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery technology with standard of care therapies to transform trea
Verano Holdings Corp. (VRNO) delivered earnings and revenue surprises of +50.00% and -1.61%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
WESTMINSTER, Colo., October 20, 2026--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard-of-care therapies and an investigational immunoth
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +53.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on TLSI today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for TLSI. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, TriSalus Life Sciences Inc. (TLSI) ranks #808 by composite RQD confidence (31/100, grade E) and #555 by equity capitalization ($237.7M). Within this direct 5-issuer industry benchmark cohort, TLSI leads on earnings valuation at N/A trailing P/E, while YDES leads on capital efficiency and profitability with -20.0% ROIC and 28.1% gross margin. YDES currently holds the highest overall quantitative score in the immediate peer group at 44/100 (D) compared with TLSI at 31/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| TLSI
ACTIVE
TriSalus Life Sciences Inc. | E | 31/100 | — | 84.6% | -35.0% | -1.78% | $237.7M | Benchmark Subject |
| BDSX Biodesix Inc. | D- | 42/100 | — | — | -35.0% | +8.14% | $260.8M | /bdsx-vs-tlsi → |
| XGN Exagen Inc. | D- | 36/100 | — | 58.3% | -35.0% | +3.57% | $210.8M | /xgn-vs-tlsi → |
| YDES YD Bio Limited | D | 44/100 | — | 28.1% | -20.0% | -6.53% | $415.8M | /ydes-vs-tlsi → |
| BNR Burning Rock Biotech Limited | E | 20/100 | — | 74.7% | -35.0% | -9.87% | $116.5M | /bnr-vs-tlsi → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), TriSalus Life Sciences Inc. (TLSI) reported GAAP revenue of $45.2M (+53.4% vs. FY2024 revenue of $29.4M , and +143.9% cumulative change since FY2023) , GAAP net income of -$39.2M, operating cash flow of -$18.0M, and free cash flow of -$18.9M (+54.0% YoY). On the balance sheet, TLSI closed FY2025 with $35.3M in total assets against $33.0M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $45.2M | -$39.2M | -$18.0M | -$18.9M | $35.3M | $33.0M |
| FY2024 (FY) | 2024-12-31 | $29.4M | -$30.0M | -$40.8M | -$41.2M | $24.0M | $22.1M |
| FY2023 (FY) | 2023-12-31 | $18.5M | -$59.4M | -$50.6M | -$50.6M | — | — |
As of 2026-11-02, TriSalus Life Sciences Inc. (NASDAQ: TLSI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $3.86 (-1.78% 1D, market cap $237.7M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 4/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, TLSI ranks #808 in composite RQD confidence.
Within the Health Care sector (Medical Specialities), TLSI carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 84.6%, and ROIC of -35.0%. By comparison, BDSX (Biodesix Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $260.8M) and XGN (Exagen Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $210.8M). Among the 5-stock peer group, TLSI leads on earnings multiple (N/A) while YDES leads on capital efficiency (-20.0% ROIC).
Per TLSI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001826667), TriSalus Life Sciences Inc. generated $45.2M in revenue (+53.4% YoY), -$39.2M in net income, and -$18.9M in free cash flow against $35.3M in total assets and $33.0M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
TLSI last traded at $3.86 (-1.78% on volume of 113,864 shares), positioning the stock -12.27% below its 50-day simple moving average ($4.40) and -12.07% below its 200-day simple moving average ($4.39). Across its 52-week range of $2.20 to $7.95, TLSI sits at the 28.9% percentile with a 14-day RSI of 44.9 (NEUTRAL RANGE) and an implied next-earnings move of ±11.8% ($3.40 to $4.32).
Why TLSI Stock slipped -1.78% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).